Pfizer Agrees to Lower Prescription Drug Costs for Medicaid in Deal with Trump Administration

Pfizer has reached an agreement with the Trump administration to lower drug costs for Medicaid, implementing most-favoured-nation pricing. This move aims to address rising healthcare costs amidst ongoing political negotiations.

President Donald Trump announced that Pfizer has agreed to reduce drug prices under a new agreement with his administration. This deal, revealed alongside Pfizer CEO Albert Bourla at the White House, is part of Trump's ongoing efforts to lower medication costs. The announcement coincided with a looming federal government shutdown due to disagreements between Democrats and Republicans over healthcare expenses.

Under this agreement, Pfizer will implement most-favoured-nation pricing for Medicaid, aligning prices with the lowest offered in other developed countries. Trump stated, "I can't tell you how big this is." Bourla added, "Today we are turning the tide and we are reversing an unfair situation." This initiative follows Trump's executive order in May, which gave drugmakers 30 days to voluntarily reduce prices or face government-imposed limits.

Focus on Drug Pricing

Trump has been vocal about the need to cut drug prices for months. He threatened tariffs to encourage pharmaceutical companies to negotiate deals, although such tariffs could potentially increase drug prices. The impact of this policy on Medicaid patients remains uncertain, as they typically pay minimal co-payments for prescriptions. However, reduced prices could benefit state budgets funding these programs and uninsured patients who lack bargaining power.

Despite Trump's claims of potential price reductions exceeding 100%, such cuts would imply drugs being free or even paying people to take them. Nonetheless, Trump is negotiating similar agreements with other pharmaceutical companies, expecting more deals soon. Besides lowering costs, Pfizer committed to investing USD 70 billion in US manufacturing facilities.

Investment in US Manufacturing

The White House has not yet disclosed specifics about Pfizer's investment, but Trump has long advocated for increased domestic drug production. Pfizer is a major US pharmaceutical company known for producing the COVID-19 vaccine Comirnaty and treatment Paxlovid, among other medications like cancer drugs and vaccines.

In late July, Trump sent letters to executives at 17 pharmaceutical firms outlining desired changes. These letters highlighted that US brand-name drug prices can be up to three times higher than international averages. Trump urged companies to adopt most-favoured-nation pricing for Medicaid and new drugs by a specified deadline.

Direct Consumer Pricing

Trump also requested that drugmakers offer reduced pricing levels for medications sold directly to consumers and businesses. He argued that high US drug prices subsidize healthcare in other nations. In recent years, some pharmaceutical companies have launched websites connecting customers directly with products like Lilly's obesity treatment Zepbound or Pfizer's blood thinner Eliquis.

This shift comes as virtual care gained popularity during the pandemic. Drug prices in the US depend on factors like competition and insurance coverage. Most Americans have insurance through employers, individual markets, or government programs like Medicaid and Medicare, which shield them from significant costs.

While Trump focused on drug costs, Democrats aimed to reverse Medicaid cuts included in a law he signed earlier this year. They sought to include this reversal in a short-term government funding measure alongside extending tax cuts that make health insurance premiums more affordable through Affordable Care Act marketplaces. Republicans have refused to negotiate on these issues.

With inputs from PTI